- As state awaits data from diabetes drug manufacturers, initial report highlights price increases (thenevadaindependent.com)
Pharmaceutical companies are preparing to submit their initial reports detailing why rising prices of some diabetes drugs have outpaced medical inflation, giving state officials the first detailed look into the costs associated with a disease that affects about a tenth of Nevadans...Despite a protracted legal battle...pharmaceutical manufacturers are required to submit reports...to comply with a new diabetes drug transparency law… the state released a list of 175 so-called national drug codes...manufacturers...are required to submit reports to the state detailing the factors that contributed to the price increases...
- Teva to recall certain blood pressure medicine in U.S. (reuters.com)
Teva Pharmaceutical Industries Ltd is recalling certain combinations of blood pressure drug valsartan in the United States following the detection of a probable cancer-causing impurity...The...drugmaker will recall all lots of amlodipine-valsartan and amlodipine-valsartan-hydrochlorothiazide combination tablets due to an impurity in an ingredient made by an India-based unit of Mylan, the U.S. Food and Drug Administration...The European Union last week effectively banned here sales of valsartan made by the Mylan India unit after some batches were found to contain the same impurity, N-nitrosodiethylamine...
- This Week in Managed Care: November 23, 2018 (ajmc.com)
Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network
- Walgreens, Humana in talks to take stakes in each other: WSJ (reuters.com)Walgreens, Humana Are in Preliminary Talks to Take Stakes in Each Other (wsj.com)
...Walgreens Boots Alliance Inc and health insurer Humana Inc are in preliminary discussions to take equity stakes in each other...Humana said it would partner with Walgreens, with its unit operating senior-focused primary care clinics inside two Walgreens stores in Kansas...The companies are discussing the possibility of expanding that venture, among other options...
- This Week in Managed Care: November 30, 2018 (ajmc.com)
Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network
- UK vows to speed up drug review in return for 2% sales cap (in-pharmatechnologist.com)
UK government and ABPI have agreed a deal to limit branded drug sales growth to 2%, potentially reducing the cost of medicine by £930m ($1.18b)...The announcement was made after the UK government and the Association of the British Pharmaceutical Industry provisionally signed the Voluntary Scheme for Branded Medicines Pricing and Access...the two key details released are: branded medicines will be subject to a 2% cap on sales growth – with pharma companies repaying the NHS for sales over this limit – and appraisals of new technology applications by NICE will be completed up to six months faster than current timelines...
- November 23 Pharmacy Week in Review: FDA Approves Rifamycin for Travelers-related Illness, Study Finds Incidence of Eczema is Much Higher Than Other Inflammatory Conditions (pharmacytimes.com)
Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- November 30 Pharmacy Week in Review: Trial Evaluating Effectiveness and Safety of Drugs Used to Treat Patients with Ebola (pharmacytimes.com)
Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- Florida’s opioid lawsuit against CVS and Walgreens takes aim at distributors with deep pockets (cnbc.com)
Florida Attorney General Pam Bondi has added Walgreens and CVS Health as defendants in the state's massive lawsuit against the opioid industry...Legal analysts say Florida and other plaintiffs are targeting the distributors and pharmacies, in part, because they have deep pockets...The...lawsuit accuses the drug stores and pharmaceutical distributors like Cardinal Health, Amerisource Bergen and McKesson of playing as big a role in the proliferation of opioid addiction as drug manufacturers like...Purdue Pharmaceuticals and Johnson & Johnson's Janssen Pharmaceuticals...
- More Pharmacists Move into Medical Practices, More Doctors See Value (drugtopics.com)
Just as hospital pharmacists moved out of the basement and into direct patient care in the 1980s and 1990s, outpatient pharmacists are moving out from behind the counter and into medical practices...There is a demand for pharmacists from the physician side in ambulatory care...Allegheny Health Network...is putting pharmacists into about 250 different practices that are part of its accountable care organization, a payment model in which the health system receives higher reimbursement if it improves quality and reduces costs…The present model, which is physician-centric, is not getting us to that quadruple aim of better outcomes, lower costs, better patient satisfaction, and improving the work life of our healthcare providers. We are moving to a patient-focused model using team-based care...The pharmacist is not able to bring in direct revenue, but you can see a decrease in 30-day readmissions, a decrease in morbidity, a decrease in ER admissions because you have a pharmacist doing medication management and reconciliation. It is a matter of recognizing that the costs you are saving are different from direct billing...